Safety and costs of treating neutropenic fever in an outpatient setting.
OBJECTIVE
The purpose of this study is to analyze the safety of outpatient treatment for cancer patients with chemotherapy-induced neutropenic fever in a community hospital setting and to compare the costs of outpatient treatment with those of inpatient treatment for such patients.


METHODS
We reviewed charts and charges for 32 consecutive patients initially treated for neutropenic fever with broad-spectrum antibiotics in the offices of Hematology/Oncology Associates (HOA) at the Bennett Cancer Center in the Stamford Hospital January 1997-June 1998. We also reviewed charts and charges for eight consecutive HOA patients with neutropenic fever who met the criteria for outpatient treatment but were initially hospitalized for other reasons during this period. We compared these two groups with respect to mean nadir absolute neutrophil count (ANC), mean number of days when ANC < 1,000 cells cu mm, and mean number of days of intravenous antibiotic treatment. We compared costs for ambulatory and hospital care of the two groups using Health Care Financing Administration (HCFA) payments in 1998 as a proxy for costs.


RESULTS
Of 32 patients with neutropenic fever initially treated in the outpatient setting, only four required hospitalization. No patients in either group died in connection with neutropenic fever. Although outpatients received an average of 3.6 days and inpatients only 2.5 days of antibiotic treatment, outpatient treatment was significantly less costly than inpatient treatment.


CONCLUSIONS
In a community hospital setting most cancer patients with neutropenic fever who meet certain criteria can be safely, effectively, and inexpensively treated as outpatients.
Del Prete
S A
SA
Bennett Cancer Center, Stamford Hospital, Connecticut, USA.
Ryan
S P
SP
Jacobson
J S
JS
Erichson
R B
RB
Weinstein
P L
PL
Grann
V R
VR
D000553:Ambulatory Care / Q000191:economics; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D003237:Connecticut; D003365:Costs and Cost Analysis; D006764:Hospitals, Community; D006801:Humans; D009503:Neutropenia / Q000188:drug therapy / Q000191:economics / Q000628:therapy*; D010044:Outpatient Clinics, Hospital / Q000191:economics; D012189:Retrospective Studies; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents